Diabetes management

Management of diabetes

Diabetes mellitus is a metabolic disease that is characterized by chronic elevated blood glucose levels (hyperglycemia). Therefore, the main goal of diabetes management is to keep blood glucose levels within normal limits or a target range as much as possible.[1] If diabetes is not well controlled, further challenges to health may occur.[1] People with diabetes can measure blood sugar by various methods, such as with a glucose meter or a continuous glucose monitor, which monitors over several days.[2] Glucose can also be measured by analysis of a routine blood sample.[2] In addition to lifestyle modification, some individuals may need medications to adequately control their blood sugar levels. Other goals of diabetes management are prevention or treatment of complications that can result from the disease itself and from its treatment.[3]

## Description

[edit]

Diabetes is a well known chronic disease that affects many individuals of all ages worldwide. There are many subtypes including Type 1, Type 2, gestational diabetes, maturity-onset diabetes of the young (MODY), neonatal diabetes, etc., with Type 1 and Type 2 being the most common.[4] It is important to have control of this condition as uncontrolled diabetes can cause many complications. Diabetes can cause acute problems such blood sugar that is too low (hypoglycemia) or too high (hyperglycemia) which can cause acute symptoms. Diabetes also affects the blood vessels in the body, which are the routes blood take to deliver nutrients and oxygen to the organs in the body.[5] By affecting the blood flow, diabetes increases the risk of other conditions such as strokes and heart disease (heart attacks).[2] Diabetes is also associated with microvascular affects (small blood vessels) in organs such as the eyes and the kidneys and can cause diabetic retinopathy and diabetic nephropathy, respectively.[5]

In addition to maintaining adequate blood sugar levels in the body, control of other risk factors that contribute to complications such as smoking, alcohol use, excessive weight, high blood pressure, and high cholesterol are also very important.[1] Often, the recommended treatment for diabetes mellitus is a combination of lifestyle changes such as increasing exercise and healthy eating, along with medications to help control the blood glucose levels in the long term.[2] In addition to management of the diabetes, it is recommended to have routine follow up with a primary care physician or endocrinologist as well a variety of specialists to assist in managing possible common complications such as foot ulcers, vision changes, and hearing loss.[6]

### Glucose Measurement

[edit]

Picture of healthcare worker using lancet to get blood sample from a person A modern portable meter for blood glucose, displaying a reading of 5.4 mmol/L (98 mg/dL) An image of a continuous glucose monitor attached on the skin

There are several methods in which blood sugar is measured including with a glucose meter, continuous glucose monitor (CGM), and routine bloodwork.

The glucose meter, also known as a glucometer, is a common and simple method using a portable electronic device to measure glucose levels either at home or in a clinical setting. The glucose meter works by taking a small sample of blood using a lancet (a sterile pointed needle) to prick a fingertip, usually the index or middle finger (Image 1). The blood droplet is usually collected at the bottom of a test strip, while the other end is inserted in the glucose meter.[7] The drop of blood is drawn into the meter and can directly measure the glucose in the sample. The units of blood sugar level from a glucose meter, will result in either mg/dL (milligrams per deciliter in the US) or mmol/L (millimoles per liter in Canada and Eastern Europe) of blood.[8] Proper user technique and environmental conditions are important in obtaining reliable readings and accurate glucose measurements.[9] Control of diabetes may be improved using home glucose meters to regularly measure glucose levels as this method provides rapid results allowing individuals to make timely decisions regarding diet, exercise, and medication.[9][10]

Continuous glucose monitors (CGMs) are another method to measure blood glucose levels and is widely used among individuals with diabetes. A continuous glucose monitor is a device that sits on the surface of the skin (usually on the arm or abdomen) and measures the amount of glucose between the cells with a probe. The device does not directly measure the blood sugar but rather tracks the interstitial glucose levels which are similar to blood glucose levels.[8][11] The other part of the CGM, known as the transmitter, then sends the information to a receiver, an insulin pump, or a compatible smart device.[12][13] Unlike the traditional glucose meter, CGMs will report the glucose level continuously and has an alarm that will alert the person if the glucose level is too high or low, helping to prevent emergencies.[8] The device is able to graph the glucose readings over the time the sensor was in use and track trends. This allows for timely adjustment of diet, activity levels, medications, and/or illness [8][14] In addition, the information from the CGM can be downloaded and sent to a second person (such as a parent, caregiver, or partner) or physician for their review.[14] CGMs have also been shown to improve glycemic control, reduce Hb A1c levels, and/or reduce the risk of hypoglycemic events.[15][12] They also can reduce the need for multiple fingersticks throughout the day, which may be preferred by some individuals. Popular CGM devices include Dexcom, Freestyle Libre, and Medtronic.[13]

In addition to the above tests, glucose can be measured on routine labs. One common test ordered by healthcare providers is a Basic Metabolic Panel which is a blood test that looks at several different substances in the body, including blood glucose.[16] Usually, individuals are told to fast for 8 hours before drawing the labs so that the provider can see the fasting glucose level.[2] The normal range for fasting blood sugar in people without diabetes is 70 to 99 mg/dL (3.9 to 5.5 mmol/L). The range for individuals considered to have prediabetes is 100 to 125 mg/dL (5.6 to 6.9 mmol/L). If the fasting blood sugar is greater than 126 mg/dL (7.0 mmol/L) on blood tests taken on separate occasions, individuals are considered to have diabetes.

Another useful test that is usually done via a blood test is the measurement of blood HbA1c (hemoglobin A1c) levels. In the blood, there is a molecule called hemoglobin which carries oxygen to the cells. Glucose can attach itself to this molecule and if the blood glucose is consistently high, the value of the A1c will increase. This test, unlike the other tests, is measured as a percentage because the test measures the proportion of all the hemoglobin that has glucose attached.[2][17] This test measures the average amount of blood sugar control over a period of about 3 months (90 days).[17] In people without diabetes, the HbA1c level ranges from 4.0 to 5.7%.[17] The range for people with prediabetes is 5.7 to 6.4%, and anything above 6.4% is considered diabetic range. Due to the HbA1c serving as a accurate indicator of overall glycemic control, regular 6 month laboratory testing of HbA1c (glycated hemoglobin) is recommended to gauge long-term control and allows for more information to then adjust a person's lifestyle as well as routine medication dosages in such cases.[18][19][20]

Optimal management of diabetes involves individuals measuring and recording their own blood glucose levels. By keeping a diary of blood glucose measurements and noting the effect of food and activity levels, individuals can modify their lifestyle to better control their diabetes. Studies suggest that the self-monitoring of blood glucose can improve HbA1c levels both in the short and long-term in patients with type 2 diabetes that are not on insulin.[21] For individuals on insulin, glucose monitoring is also crucial in achieving effective dosing and timing.

### Glycemic Control

[edit]

Glycemic control is a medical term referring to the typical levels of blood glucose in a person with diabetes mellitus. Much evidence suggests that many of the long-term complications of diabetes, result from many years of hyperglycemia (elevated levels of glucose in the blood).[22]

"Perfect glycemic control" would mean that glucose levels were always normal (70–130 mg/dL or 3.9–7.2 mmol/L) and indistinguishable from a person without diabetes. Good glycemic control, in the sense of a "target" for treatment, has become an important goal of diabetes care. Poor glycemic control refers to persistent (over several months) elevated blood glucose in the 200 to 500 mg/dL (11–28 mmol/L) range. This is also measured by Hb A1c levels, which may range 6.5% or higher.[4]

### Goals

[edit]

They are suggested in clinical practice guidelines released by various national and international diabetes organizations.[23][24]

The glycemic targets are:

* HbA1c of less than 7.0% if they are achievable without significant hypoglycemia[25][26]
* Preprandial (before eating) blood glucose: 70 to 130 mg/dL (3.9 to 7.2 mmol/L)[25]
* 2-hour postprandial (after eating) blood glucose: Less than 180 mg/dL (<10 mmol/L)[25]

Goals should be individualized based on:[25]

* Duration of diabetes
* Age/life expectancy
* Comorbidity
* Known cardiovascular disease or advanced microvascular disease
* Hypoglycemia awareness

In older people, clinical practice guidelines by the American Geriatrics Society recommend, in frail people who have a life expectancy of less than 5 years, a target a Hb A1c of 8% is appropriate as the risk of very low blood sugar outweighs the long term benefits of a lower A1c.[27]

When comparing the effects of tight versus conventional (more relaxed) glycemic control in type 2 diabetics, studies failed to demonstrate a difference in all-cause cardiovascular death, non-fatal stroke, or limb amputation, but decreased the risk of nonfatal myocardial infarction (heart attack) by 15%.[28] Additionally, tight glucose control decreased the risk of progression of kidney, nerve, and eye complications, but increased the risk of severe hypoglycemia.[28]

## Lifestyle Modification

[edit]

### Diet

[edit]

Main article: Diet in diabetes

Dietary changes have been shown to significantly help patients manage diabetes.[29] There are many diets that are effective at managing diabetes however, it is important that patients understand that there is no one diet that all patients should use.[30] Some diets that have strong evidence and have commonly been used successfully in diabetes management and assist with weight loss include Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH), Alternative Healthy Eating Index (AHEI), vegetarian, low carb, or carb-controlled.[30][31] In addition, it is recommended that individuals choose a diet that can be adhered to long-term. Even in the most ideal diet becomes impractical if the patient has difficulty following it.[30]

A regular diet that has reduced variability in carbohydrates is an important factor in producing normal blood sugars. Patients with diabetes should eat preferably a balanced and healthy diet. Meals should consist of half a plate of non-starchy vegetables, 1/4 plate of lean protein, and 1/4 plate of starch/grain.[30] Patients should avoid excess simple carbs or added fat (such as butter, salad dressing) and instead eat complex carbohydrates such as whole grains.[1] In addition, patients should also avoid consumption of processed meat and foods and sugar-sweetened beverages. In the long term, it is helpful to eat a consistent diet and amount of carbohydrate to make blood sugar management easier.[32] It is important for patients to eat 3 meals a day in order to reduce the chances of hypoglycemia, especially with patients that take insulin.[1]

There is a lack of evidence of the usefulness of low-carbohydrate dieting for people with type 1 diabetes (T1D).[33] Although for certain individuals it may be feasible to follow a low-carbohydrate regime combined with carefully managed insulin dosing, this is hard to maintain and there are concerns about potential adverse health effects caused by the diet.[33] In general people with T1D are advised to follow an individualized eating plan rather than a pre-decided one.[33]

### Physical Activity/Exercise

[edit]

Along with diet, physical activity is also important for the management of diabetes. Not only does exercising regularly help manage blood sugar levels and weight, it helps reduce the risk of heart attack and stroke, reduces cholesterol and blood pressure levels, reduces risk of diabetes related complications, increases the effect of insulin, provides a boost in energy levels, helps reduce stress, and contributes to positive self-esteem.[34] By exercising, the body becomes more sensitive to insulin, allowing for better absorption of glucose by the muscle cells, for up to 24 hours after exercise.[35][36] In addition, studies have shown that physical activity, even below recommended amounts, has the ability to reduce risk fo diabetic-related complications.[37]

In people with type 2 diabetes, the combination of aerobic ("cardio") exercise and strength training is effective.[38] Aerobic exercise has been shown to largely improve HbA1c, and contributes to weight loss and the enhanced regulation of cholesterol and lipoproteins.[36] This may be any form of continuous exercise that elevates breathing and heart rate, such as walking, swimming, or dancing.[38] During the last 20 years, resistance training has gained recognition as an effective form of exercise for people with type 2 diabetes.[36]

In youths with type 1 diabetes, there is an association between exercise and lower HBA1c.[39] Furthermore, studies have shown that the longer the length of the exercise program, the better the reduction in HBA1c and insulin requirements.[39][40]

### Weight Loss

[edit]

Image of waist circumference, comparing a normal weight to an overweight and obese individual.

In addition to diet and exercise, weight loss is an important tool to help with diabetes management. T2D is often associated with obesity and increased abdominal circumference.[41] Often patients who are at risk of diabetes may be able to reverse their progression to T2D with weight loss as well.[41] Weight loss can help improve metabolic control, reduce the risk of further complications, other health related problems, and helps improve the effects of insulin on the body.[41][42] Weight loss helps reduce the destruction of the beta cells, which produce insulin in the body, as well.[41]

It is recommended for patients who have been diagnosed with T2D who are overweight or obese to lose at least 5% of their weight and maintain the weight loss. There have been studies that have demonstrated that by losing about 5 to 10% of their weight at diagnosis, there is a reduction in heart disease risk factors, lowered Hb A1c, less diabetes medications, lower cholesterol and improved fitness.[41]

Common strategies to help reduce weight many include lifestyle measures such as diet and exercise, behavioral therapy, pharmacologic interventions, and surgery. The goal of weight loss and method for achievement should be individualized based on the patient's desires and motivation.[41] It is important for providers to help maintain patient motivation and provide education to assist individuals in their weight journey.[43] Additionally, some medications that reduce blood sugars such as insulin may initially cause weight gain due to the increased conversion of blood sugar to stored forms such as fat.[41] Therefore, in patients with diabetes, providers may try other medications that lower blood sugar but not cause as much weight gain.[41]

## Medications

[edit]

Main article: Anti-diabetic drug

There are several medications classes that are commonly used to control blood sugar levels in patients with diabetes. Most of the medications used are either oral or injected.[1] In patients with T1D, insulin is required because the body no longer produces insulin.[2] In patients with T2D, management is largely more variable as lifestyle changes can have a significant impact. However, medications may be added to further help control blood glucose levels if the lifestyle changes are not effectively controlling the condition. Unlike patients with type 1 diabetes, patients with T2D can still produce insulin, so usually oral medications are recommended as first line treatment before requiring insulin for diabetic control.[2] Patient education[44] and adherance with treatment is very important in managing the disease. Improper use of medications and insulin can be very dangerous causing hypo- or hyper-glycemic episodes.

### Insulin

[edit]

Main article: Insulin therapy

Insulin pen used to administer insulin

Insulin is the hormone that is made by the body that controls the cell intake of glucose. Normally, the pancreas produces insulin in response to high glucose levels in the body to bring the blood glucose levels down. For those with type 1 diabetes, there will always be a need for insulin injections throughout their life, as the pancreatic beta cells are not capable of producing sufficient insulin.[45] Insulin can not be taken orally because insulin is a hormone and is destroyed by the digestive track. Insulin can be injected by several methods, including a hypodermic needle, jet injector, or insulin pump. There is also inhaled insulin that can be used in adults with diabetes.[46]

There are several types of insulin that are commonly used in medical practice, with varying times of onset and duration of action.[45] These include:

* Rapid acting (i.e. insulin lispro) with onset in 15 minutes and duration of about 4 hrs
* Short acting (i.e. regular insulin) with onset in 30 minutes and duration of about 6 hrs
* Intermediate acting (i.e NPH insulin) with onset in 2 hours and duration of about 14 hrs
* Long acting (i.e. detemir) with onset in 1 hour and duration of about 24 hrs
* Premixed which are usually combinations of short and long acting insulin

Insulin is usually taken several times per day in patients who require it to control their diabetes.[45] Patients usually take long acting insulin once per day and then take insulin before meals. The time of onset of the insulin determines how far in advance patients should take the insulin before they eat.[45]

Insulin therapy requires close monitoring and a great deal of patient education, as improper administration is quite dangerous. Insulin can easily cause hypoglycemia if the patient does not eat after administering insulin or accidentally took too much insulin.[45] A previously satisfactory dosing may be too much if less food is consumed causing hypoglycemia.[45] Exercise decreases insulin requirements as exercise increases glucose uptake by body cells whose glucose is controlled by the insulin.[38]

Insulin therapy creates risk because of the inability to continuously know a person's blood glucose level and adjust insulin infusion appropriately. However, new advances in technology have significantly alleviated many of these risks, although they can still occur.[47][48] Small, portable insulin infusion pumps are available from several manufacturers. They allow a continuous infusion of small amounts of insulin to be delivered through the skin around the clock. They also have the ability to give bolus doses when a person eats or has elevated blood glucose levels. They are also capable to being used in conjunction with continuous glucose monitors for optimal glucose management. This is very similar to how the pancreas works, but these pumps lack a continuous "feed-back" mechanism. Thus, the user is still at risk of giving too much or too little insulin unless blood glucose measurements are made.

### Oral Medications

[edit]

#### Metformin

[edit]

One of the most common drugs used in T2D, metformin is the drug of choice to help patients lower their blood sugar levels. Metformin is an example of a class of medicine called biguanides.[49] The medication works by reducing the new creation of glucose from the liver and by reducing absorption of sugar from food.[49] In addition, the medication also works to help increase the effects of insulin on muscle cells, which take in glucose.[50] The medicine is not used for T1D as these patients do not produce any insulin and metformin relies on some insulin production in order to be effective.[49] There are several preparations of the medication such as tablets, extend release tablets, and liquid suspensions. Metformin is usually started as 500 to 1000 mg tablets twice a day by mouth (PO), usually with meals.[49] If taking the extended release tablets, they should be always swallowed whole as cutting the tablet will cause faster release of the medication.[49] The medication most commonly may cause side effects such as stomach upset and diarrhea, but in general is well tolerated and has a relatively low chance of causing hypoglycemia.[50] One rare (about 1% chance) but serious side effect of metformin is that it can cause lactic acidosis, usually in patients with poor kidney function.[50] To assist in tolerance of the metformin, practitioners may recommend gradual increase of the dose of the medication.

#### Sulfonylureas

[edit]

Another commonly used class of medications to treat T2D are sulfonylureas. This class of medicine increases the release of insulin from the beta cells in the pancreas. The medication can not be used in patients with T1D, as they do not have functioning beta cells and can not produce insulin.[50] Some common examples of a sulfonylurea is glipizide, glyburide, glimepiride and gliclazide. Depending on the medication, there are different size tablets but in general, the sizes range from about 1 mg to 10 mg. Usually, the tablet is taken about 30 minutes before a meal and can be either once or twice a day. The most common adverse effects of the medication are lightheadedness and stomach irritation.[50] Sulfonylureas have a greater risk of hypoglycemia but the risk is still only around 3% of patients who use them.[50] In patients who have a greater risk of low sugar, such as in the elderly and patients with kidney disease, the starting dose can be as low as 0.5 mg.

### GLP-1 agonists

[edit]

Another popular medication that is used in T2D management are glucagon like peptide 1 (GLP-1) agonists. This class of medication works by mimicking a hormone called glucagon-like peptide which has many effects in the body.[51] One effect of the hormone is that it helps time the release of insulin when patients eat and the blood glucose rises.[52] In addition, it can significantly increase the amount of insulin release.[53] Lastly, the medication also slows down the movement of food through the digestive tract and can increase feeling of fullness while eating, decreasing appetite and weight.[52] These drugs are very effective at controlling T2D and reducing risk of heart attacks, strokes, and other complications due to diabetes. In addition, patients usually lose weight and have improved blood pressure and cholesterol.[51] Common names of these medications include semaglutide (Ozempic and Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity).[51] These medications must be injected and are usually injected in the upper arm, thighs or stomach areas.[52] They are usually given once a week but some of the medication can be as frequent as twice daily.[51] The dose is usually started low and tapered gradually. Some of the common side effects of the medication is nausea, vomiting, and diarrhea. Patients with a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 should not be prescribed the drug as it may increase the risk of developing cancer.[52]

## Surgery

[edit]

While weight loss is beneficial in improving glycemic control in patients with T2D,[54] maintaining significant weight loss can be challenging. People with diabetes who have a body mass index (BMI) of 35 or higher, and who have been unable to lose weight otherwise, bariatric surgery offers a viable option to help achieve that goal. In 2018, a Patient-Centered Outcomes Research Institute funded study was published which analyzed the effects of three common types of bariatric surgery on sustained weight loss and long-lasting glycemic control in patients with T2D.[55] The results of this study demonstrated that five years after bariatric surgery, there was significant weight loss in a large majority of patients. In addition, and more importantly, this study showed that, in patients with type 2 diabetes with a BMI of 35 or higher, bariatric surgery has the potential to lead to complete remission of diabetes in as many as 40% of those people who have the procedure.[56] Like any operation, bariatric surgery is not without risks and complications, and those risks need to weighed against the potential benefits in anyone considering the procedure.

## Additional Monitoring

[edit]

### Foot Care

[edit]

Foot monitoring can help in predicting the likelihood of developing diabetic foot ulcers, a common complication in persistent uncontrolled diabetes.[57] A common method for this is using a special thermometer to look for spots on the foot that have higher temperature which indicate the possibility of an ulcer developing.[58] At the same time there is no strong scientific evidence supporting the effectiveness of at-home foot temperature monitoring.[59] The current guideline in the United Kingdom recommends collecting 8-10 pieces of information for predicting the development of foot ulcers.[60] A simpler method proposed by researchers provides a more detailed risk score based on three pieces of information (insensitivity, foot pulse, previous history of ulcers or amputation). This method is not meant to replace individuals regularly checking their own feet but complement it.[58][61]

### Dental Care

[edit]

High blood glucose levels in individuals with diabetes is a risk factor for developing gum and tooth problems. For patients with diabetes, there are increased risk of developing oral health problems such as tooth decay, saliva production dysfunction, fungal infections, and periodontal disease[62] Diabetes lowers the ability to resist infection and also slows healing and therefore individuals may experience more severe periodontitis.[63] In turn, the chronic infection from periodontal disease can cause difficulties in controlling diabetes, leading to worsening of diabetic complications.[64] The oral problems in persons with diabetes can be prevented with a good control of the blood sugar levels, regular check-ups with their dental provider, and good oral hygiene. Looking for early signs of gum disease (redness, swelling, bleeding gums) and informing the dentist about them is also helpful in preventing further complications. Quitting smoking is recommended to avoid serious diabetes complications and oral diseases. By maintaining a good oral status, diabetic persons prevent losing their teeth as a result of various periodontal conditions.

### Eye Care

[edit]

Any individual with diabetes is at risk for diabetes-related eye conditions and it is recommended to have an initial diabetic eye exam screening and subsequent annual comprehensive dilated eye exam with either an optometrist or ophthalmologist.[65] Diabetic retinopathy is the most common complication of diabetes and one of the leading causes of blindness worldwide. Individuals with diabetes are at greater risk for developing eye conditions such as glaucoma and cataracts earlier or more frequently. Blood sugar control continues to be the most effective way to decrease the risk or slow the progression of diabetic retinopathy.[66]

### Digital Tools

[edit]

#### Electronic Health Records

[edit]

Sharing their electronic health records with people who have T2D helps them to reduce their blood sugar levels. It is a way of helping people understand their own health condition and involving them actively in its management.[67][68]

#### m-health Monitoring Applications

[edit]

The widespread use of smartphones has turned mobile applications (apps) into a popular means of the usage of all forms of software.[69] The number of health-related apps accessible in the App Store and Google Play is approximately 100,000, and among these apps, the ones related to diabetes are the highest in number. Conducting regular self-management tasks such as medication and insulin intake, blood sugar checkup, diet observance, and physical exercise are really demanding.[70] This is why the use of diabetes-related apps for the purposes of recording diet and medication intake or blood glucose level is promising to improve the health condition for diabetic people.

## Complexities

[edit]

Daily glucose and insulin cycle

The main complexities stem from the nature of the feedback loop of glucose in the blood stream.

* The glucose cycle is a system which is affected by two factors: entry of glucose into the bloodstream and also blood levels of insulin to control its transport out of the bloodstream
* As a system, it is sensitive to diet and exercise
* It is affected by the need for patient anticipation due to the complicating effects of time delays between any activity and the respective impact on the glucose
* Management is highly intrusive, and compliance is an issue, since it relies upon user lifestyle change and often upon regular sampling and measuring of blood glucose levels, multiple times a day in many cases
* It changes as people grow and develop
* It is highly individual

As diabetes is a prime risk factor for cardiovascular disease, controlling other risk factors which may give rise to secondary conditions, as well as the diabetes itself, is one of the facets of diabetes management. Checking cholesterol, LDL, HDL and triglyceride levels may indicate hyperlipoproteinemia, which may warrant treatment with hypolipidemic drugs. Checking the blood pressure and keeping it within strict limits (using diet and antihypertensive treatment) protects against the retinal, renal and cardiovascular complications of diabetes. Regular follow-up by a podiatrist or other foot health specialists is encouraged to prevent the development of diabetic foot. Annual eye exams are suggested to monitor for progression of diabetic retinopathy.[71]

### Hypoglycemia

[edit]

Paramedics attend a diabetic man who lost control of his vehicle due to low blood sugar (hypoglycemia)

A level of <70 mg/dL (<3.8 mmol/L) is described as a hypoglycemic attack (low blood sugar). Most diabetics know when they are hypoglycemic and seek food or a sweet drink to raise their glucose levels. Intensive efforts to achieve blood sugar levels close to normal have been shown to triple the risk of the most severe form of hypoglycemia, in which the person requires assistance from by-standers in order to treat the episode.[72] Among intensively controlled type 1 diabetics, 55% of episodes of severe hypoglycemia occur during sleep, and 6% of all deaths in diabetics under the age of 40 are from hypoglycemia at night.[73]

Hypoglycemia can be problematic if it occurs while driving as it can affect a person's thinking process, coordination, and state of consciousness.[74][75] Some people are more prone to hypoglycemia as they have reported fewer warning symptoms, and their body released less epinephrine (a hormone that helps raise blood glucose).[76] Additionally, individuals with a history of hypoglycemia-related driving mishaps appear to use sugar at a faster rate.[77]

Drivers with diabetes susceptible to driving mishaps should monitor their blood sugar to be not less than 70 mg/dL (3.9 mmol/L). Instead, these drivers are advised to treat hypoglycemia and delay driving until their blood glucose is above 90 mg/dL (5 mmol/L).[76]

### Hyperglycemia

[edit]

A patient is considered to have hyperglycemia (high glucose) if the patient has a sugar level of greater than 230–270 mg/dL (13–15 mmol/L). Sometimes patient may be temporarily hypoglycemic under certain conditions (e.g. not eating regularly, or after strenuous exercise). Patients should closely monitor their sugar levels to ensure that they reduce rather than continue to remain high. High blood sugar levels are not as easy to detect as hypoglycemia and usually happens over a period of days rather than hours or minutes. If left untreated, this can result in diabetic coma and death.

Prolonged and elevated levels of glucose in the blood, which is left unchecked and untreated, will, over time, result in serious diabetic complications in those susceptible and sometimes even death. There is currently no way of testing for susceptibility to complications. Diabetics are therefore recommended to check their blood sugar levels either daily or every few days. There is also diabetes management software available from blood testing manufacturers which can display results and trends over time.

### Medication nonadherence

[edit]

Because many patients with diabetes have two or more comorbidities, they often require multiple medications. The prevalence of medication nonadherence is high among patients with chronic conditions, such as diabetes, and nonadherence is associated with public health issues and higher health care costs. One reason for nonadherence is the cost of medications. Being able to detect cost-related nonadherence is important for health care professionals, because this can lead to strategies to assist patients with problems paying for their medications. Some of these strategies are use of generic drugs or therapeutic alternatives, substituting a prescription drug with an over-the-counter medication, and pill-splitting. Interventions to improve adherence can achieve reductions in diabetes morbidity and mortality, as well as significant cost savings to the health care system.[78] Smartphone apps have been found to improve self-management and health outcomes in people with diabetes through functions such as specific reminder alarms,[79] while working with mental health professionals has also been found to help people with diabetes develop the skills to manage their medications and challenges of self-management effectively.[80]

### Psychological mechanisms and adherence

[edit]

As self-management of diabetes typically involves lifestyle modifications, adherence may pose a significant self-management burden on many individuals.[81] For example, individuals with diabetes may find themselves faced with the need to self-monitor their blood glucose levels, adhere to healthier diets and maintain exercise regimens regularly in order to maintain metabolic control and reduce the risk of developing cardiovascular problems. Barriers to adherence have been associated with key psychological mechanisms: knowledge of self-management, beliefs about the efficacy of treatment and self-efficacy/perceived control.[81] Such mechanisms are inter-related, as one's thoughts (e.g. one's perception of diabetes, or one's appraisal of how helpful self-management is) is likely to relate to one's emotions (e.g. motivation to change), which in turn, affects one's self-efficacy (one's confidence in their ability to engage in a behaviour to achieve a desired outcome).[82]

As diabetes management is affected by an individual's emotional and cognitive state, there has been evidence suggesting the self-management of diabetes is negatively affected by diabetes-related distress and depression.[83] There is growing evidence that there is higher levels of clinical depression in patients with diabetes compared to the non-diabetic population.[84][85] Depression in individuals with diabetes has been found to be associated with poorer self-management of symptoms.[86] This suggests that it may be important to target mood in treatment. In the case of children and young people, especially if they are socially disadvantaged, research suggests that it is important that healthcare providers listen to and discuss their feelings and life situation to help them engage with diabetes services and self-management.[87][88]

To this end, treatment programs such as the Cognitive Behavioural Therapy - Adherence and Depression program (CBT-AD) have been developed to target the psychological mechanisms underpinning adherence.[80]

## See also

[edit]

* Ambulatory care sensitive conditions
* Diabetes and exercise
* Diabetic coma
* Diabetic hypoglycemia
* Diabetic Hypoglycemia (journal)
* Glycemic efficacy
* Latent autoimmune diabetes of adults

## References

[edit]

1. ^ a b c d e f "TDS Health". online.statref.com. Retrieved 30 October 2024.
2. ^ a b c d e f g h "Diabetes - NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 30 October 2024.
3. ^ Simó R, Hernández C (August 2002). "[Treatment of diabetes mellitus: general goals, and clinical practice management]". Revista Espanola de Cardiologia. 55 (8): 845–860\. doi:10.1016/s0300-8932(02)76714-6. PMID 12199981.
4. ^ a b Sapra A, Bhandari P (2025), "Diabetes", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31855345, retrieved 7 April 2025
5. ^ a b Kushner PR, Cavender MA, Mende CW (14 October 2022). "Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases". Clinical Diabetes. 40 (4): 401–412\. doi:10.2337/cd21-0119. ISSN 0891-8929. PMC 9606551. PMID 36381309.
6. ^ CDC (26 July 2024). "Your Diabetes Care Schedule". Diabetes. Retrieved 6 November 2024.
7. ^ "Monitoring blood glucose - Series—Record your reading: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 31 October 2024.
8. ^ a b c d "Monitoring Your Blood". Diabetes Education Online. Retrieved 31 October 2024.
9. ^ a b Tonyushkina K, Nichols JH (July 2009). "Glucose Meters: A Review of Technical Challenges to Obtaining Accurate Results". Journal of Diabetes Science and Technology. 3 (4): 971–980\. doi:10.1177/193229680900300446. ISSN 1932-2968. PMC 2769957. PMID 20144348.
10. ^ "Blood glucose and blood sugar are interchangeable terms, and both are crucial to the health of the body; especially for people with diabetes". Diabetes. 15 January 2019. Retrieved 12 September 2021.
11. ^ Wood A, O'Neal D, Furler J, et al. (May 2018). "Continuous glucose monitoring: a review of the evidence, opportunities for future use and ongoing challenges". Internal Medicine Journal. 48 (5): 499–508\. doi:10.1111/imj.13770. ISSN 1444-0903. PMID 29464891.
12. ^ a b Rodbard D (February 2016). "Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities". Diabetes Technology & Therapeutics. 18 (S2): S2–3–S2-13. doi:10.1089/dia.2015.0417. ISSN 1520-9156. PMC 4717493. PMID 26784127.
13. ^ a b "Continuous Glucose Monitoring - NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 10 April 2025.
14. ^ a b Miller EM (1 December 2020). "Using Continuous Glucose Monitoring in Clinical Practice". Clinical Diabetes. 38 (5): 429–438\. doi:10.2337/cd20-0043. ISSN 0891-8929. PMC 7755046.
15. ^ Park C, Le QA (September 2018). "The Effectiveness of Continuous Glucose Monitoring in Patients with Type 2 Diabetes: A Systematic Review of Literature and Meta-analysis". Diabetes Technology & Therapeutics. 20 (9): 613–621\. doi:10.1089/dia.2018.0177. ISSN 1520-9156. PMID 30095980.
16. ^ "Basic Metabolic Panel (BMP): MedlinePlus Medical Test". medlineplus.gov. Retrieved 31 October 2024.
17. ^ a b c "A1C". medlineplus.gov. Retrieved 31 October 2024.
18. ^ Sherwani SI, Khan HA, Ekhzaimy A, et al. (January 2016). "Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients". Biomarker Insights. 11: BMI.S38440. doi:10.4137/BMI.S38440. ISSN 1177-2719. PMC 4933534.
19. ^ Zhang X, Gregg EW, Williamson DF, et al. (1 July 2010). "A1C Level and Future Risk of Diabetes: A Systematic Review". Diabetes Care. 33 (7): 1665–1673\. doi:10.2337/dc09-1939. hdl:10044/1/71801. ISSN 0149-5992.
20. ^ "Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus". Diabetes Research and Clinical Practice. 93 (3): 299–309\. September 2011. doi:10.1016/j.diabres.2011.03.012. ISSN 0168-8227.
21. ^ Zhu H, Zhu Y, Leung Sw (September 2016). "Is self-monitoring of blood glucose effective in improving glycaemic control in type 2 diabetes without insulin treatment: a meta-analysis of randomised controlled trials". BMJ Open. 6 (9): e010524. doi:10.1136/bmjopen-2015-010524. ISSN 2044-6055. PMC 5020874. PMID 27591016.
22. ^ Nanayakkara N, Curtis AJ, Heritier S, et al. (February 2021). "Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses". Diabetologia. 64 (2): 275–287\. doi:10.1007/s00125-020-05319-w. ISSN 0012-186X. PMC 7801294. PMID 33313987.
23. ^ "Practice Guidelines Resources". American Diabetes Association. Retrieved 12 July 2023.
24. ^ Hur KY, Moon MK, Park JS, et al. (31 July 2021). "2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association". Diabetes & Metabolism Journal. 45 (4). Korean Diabetes Association: 461–481\. doi:10.4093/dmj.2021.0156. ISSN 2233-6079. PMC 8369224. PMID 34352984.
25. ^ a b c d American Diabetes Association (January 2019). "6. Glycemic Targets: Standards of Medical Care in Diabetes-2019". Diabetes Care. 42 (Suppl 1): S61 – S70. doi:10.2337/dc19-S006. PMID 30559232.
26. ^ Qaseem A, Vijan S, Snow V, et al. (September 2007). "Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians". Annals of Internal Medicine. 147 (6): 417–422\. doi:10.7326/0003-4819-147-6-200709180-00012. PMID 17876024.
27. ^ Brown AF, Mangione CM, Saliba D, et al. (May 2003). "Guidelines for improving the care of the older person with diabetes mellitus". Journal of the American Geriatrics Society. 51 (5 Suppl Guidelines): S265 – S280. doi:10.1046/j.1532-5415.51.5s.1.x. PMID 12694461. S2CID 9149226.
28. ^ a b Buehler AM, Cavalcanti AB, Berwanger O, et al. (June 2013). "Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials". Cardiovascular Therapeutics. 31 (3): 147–160\. doi:10.1111/j.1755-5922.2011.00308.x. PMID 22212499.`{{cite journal}}`: CS1 maint: overridden setting (link)
29. ^ Patel R, Sina RE, Keyes D (2025), "Lifestyle Modification for Diabetes and Heart Disease Prevention", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 36251831, retrieved 7 April 2025
30. ^ a b c d McDermott M (2022). Diabetes Secrets. Elsevier. pp. 52–54\. ISBN 978-0-323-79262-2.
31. ^ Jannasch F, Kröger J, Schulze MB (1 June 2017). "Dietary Patterns and Type 2 Diabetes: A Systematic Literature Review and Meta-Analysis of Prospective Studies". The Journal of Nutrition. 147 (6): 1174–1182\. doi:10.3945/jn.116.242552. PMID 28424256.
32. ^ "I have Type 1 diabetes – what can I eat?". Diabetes UK. Retrieved 14 June 2019.
33. ^ a b c Seckold R, Fisher E, de Bock M, et al. (March 2019). "The ups and downs of low-carbohydrate diets in the management of Type 1 diabetes: a review of clinical outcomes". Diabetic Medicine (Review). 36 (3): 326–334\. doi:10.1111/dme.13845. PMID 30362180. S2CID 53102654. "Low‐carbohydrate diets are of interest for improving glycaemic outcomes in the management of Type 1 diabetes. There is limited evidence to support their routine use in the management of Type 1 diabetes."
34. ^ "Managing Diabetes". Diabetes Research Institute Foundation. 2023. Retrieved 1 December 2022.
35. ^ "Blood Sugar and Exercise". American Diabetes Association. 2025. Retrieved 20 November 2022.
36. ^ a b c Kirwan JP, Sacks J, Nieuwoud S (July 2017). "The essential role of exercise in the management of type 2 diabetes". Cleveland Clinic Journal of Medicine. 84 (7 Suppl 1): S15 – S21. doi:10.3949/ccjm.84.s1.03. ISSN 0891-1150. PMC 5846677. PMID 28708479.
37. ^ Rietz M, Lehr A, Mino E, et al. (1 December 2022). "Physical Activity and Risk of Major Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review and Meta-Analysis of Observational Studies". Diabetes Care. 45 (12): 3101–3111\. doi:10.2337/dc22-0886. ISSN 0149-5992.
38. ^ a b c "Physical Activity and Diabetes, chapter 10". Diabetes Canada. 2018. Retrieved 1 December 2022.
39. ^ a b García-Hermoso A, Ezzatvar Y, Huerta-Uribe N, et al. (June 2023). "Effects of exercise training on glycaemic control in youths with type 1 diabetes: A systematic review and meta-analysis of randomised controlled trials". European Journal of Sport Science. 23 (6): 1056–1067\. doi:10.1080/17461391.2022.2086489. hdl:2454/43706. ISSN 1746-1391. PMID 35659492.
40. ^ Lumb A (1 December 2014). "Diabetes and exercise". Clinical Medicine. 14 (6): 673–676\. doi:10.7861/clinmedicine.14-6-673. ISSN 1470-2118. PMC 4954144. PMID 25468857.
41. ^ a b c d e f g h McDermott MT, Trujillo JM (2022). Diabetes secrets. Philadelphia, PA: Elsevier. ISBN 978-0-323-79262-2.
42. ^ "Losing Weight & Diabetes | ADA". diabetes.org. Retrieved 6 November 2024.
43. ^ Maula A, Kai J, Woolley AK, et al. (April 2020). "Educational weight loss interventions in obese and overweight adults with type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials". Diabetic Medicine. 37 (4): 623–635\. doi:10.1111/dme.14193. ISSN 0742-3071. PMC 7154644.
44. ^ Mannucci E, Giaccari A, Gallo M, et al. (February 2022). "Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails". Nutrition, Metabolism, and Cardiovascular Diseases. 32 (2): 330–336\. doi:10.1016/j.numecd.2021.10.005. PMID 34893413. S2CID 244580173.`{{cite journal}}`: CS1 maint: overridden setting (link)
45. ^ a b c d e f "TDS Health". online.statref.com. Retrieved 31 October 2024.
46. ^ "Insulin, Medicines, & Other Diabetes Treatments - NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 31 October 2024.
47. ^ Kalra S, Pathan F, Kshanti IA, et al. (November 2023). "Optimising Insulin Injection Techniques to Improve Diabetes Outcomes". Diabetes Therapy. 14 (11): 1785–1799\. doi:10.1007/s13300-023-01460-y. ISSN 1869-6953. PMC 10570228.
48. ^ Kerr D, Edelman S, Vespasiani G, et al. (August 2022). "New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes". Endocrine Practice. 28 (8): 811–821\. doi:10.1016/j.eprac.2022.04.006.
49. ^ a b c d e "Metformin: MedlinePlus Drug Information". medlineplus.gov. Retrieved 5 November 2024.
50. ^ a b c d e f Ganesan K, Rana MB, Sultan S (2024), "Oral Hypoglycemic Medications", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29494008, retrieved 5 November 2024
51. ^ a b c d "GLP-1 agonists: Diabetes drugs and weight loss - Mayo Clinic". www.mayoclinic.org. Retrieved 7 November 2024.
52. ^ a b c d "Semaglutide Injection: MedlinePlus Drug Information". medlineplus.gov. Retrieved 7 November 2024.
53. ^ Nauck MA, Meier JJ (February 2018). "Incretin hormones: Their role in health and disease". Diabetes, Obesity and Metabolism. 20 (S1): 5–21\. doi:10.1111/dom.13129. ISSN 1462-8902. PMID 29364588.
54. ^ McCombie L, Leslie W, Taylor R, et al. (13 September 2017). "Beating type 2 diabetes into remission". BMJ. 358: j4030. doi:10.1136/bmj.j4030. ISSN 0959-8138. PMID 28903916. S2CID 28182743.
55. ^ Arterburn D, Wellman R, Emiliano A, et al. (4 December 2018). "Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study". Annals of Internal Medicine. 169 (11): 741–750\. doi:10.7326/M17-2786. ISSN 0003-4819. PMC 6652193. PMID 30383139.
56. ^ Anau J, Arterburn D, Coleman KJ, et al. (2 November 2020). "Comparing Three Types of Weight Loss Surgery—The PCORnet Bariatric Study". Patient-Centered Outcomes Research Institute. doi:10.25302/11.2020.obs.150530683. S2CID 228814682.
57. ^ Boulton A, Armstrong D, Krisner R, et al. (October 2018). "Diagnosis and Management of Diabetic Foot Complications". ADA Clinical Compendia. 2018 (2): 1–20\. doi:10.2337/db20182-1.
58. ^ a b "Simple tool identifies the people with diabetes most likely to develop foot ulcers". NIHR Evidence. National Institute for Health and Care Research. 21 June 2022. doi:10.3310/nihrevidence_51316. S2CID 251787297.
59. ^ Golledge J, Fernando ME, Alahakoon C, et al. (23 May 2022). "Efficacy of at home monitoring of foot temperature for risk reduction of diabetes-related foot ulcer: A meta-analysis". Diabetes/Metabolism Research and Reviews. 38 (6): e3549. doi:10.1002/dmrr.3549. ISSN 1520-7552. PMC 9541448. PMID 35605998. S2CID 251981184.
60. ^ "Diabetic foot problems: prevention and management". National Institute for Health and Care Excellence (NICE). 26 August 2015. Retrieved 6 September 2022.
61. ^ Chappell FM, Crawford F, Horne M, et al. (25 May 2021). "Development and validation of a clinical prediction rule for development of diabetic foot ulceration: an analysis of data from five cohort studies". BMJ Open Diabetes Research & Care. 9 (1): e002150. doi:10.1136/bmjdrc-2021-002150. ISSN 2052-4897. PMC 8154962. PMID 34035053.
62. ^ "Oral diabetes care". Retrieved 5 May 2010.
63. ^ Koh GC, Peacock SJ, van der Poll T, et al. (April 2012). "The impact of diabetes on the pathogenesis of sepsis". European Journal of Clinical Microbiology & Infectious Diseases. 31 (4): 379–388\. doi:10.1007/s10096-011-1337-4. PMC 3303037. PMID 21805196.
64. ^ "Gum Disease and Diabetes". Archived from the original on 12 June 2010. Retrieved 5 May 2010.
65. ^ Cooper B (July 2022). "Ten Key Elements of a Diabetes-Related Eye Examination". ADA Clinical Compendia. 2022 (3): 4–7\. doi:10.2337/db20223-4.
66. ^ American Diabetes Association Professional Practice Committee (1 January 2022). "12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022". Diabetes Care. 45 (Supplement_1): S185 – S194. doi:10.2337/dc22-S012. ISSN 0149-5992.
67. ^ Neves AL, Freise L, Laranjo L, et al. (December 2020). "Impact of providing patients access to electronic health records on quality and safety of care: a systematic review and meta-analysis". BMJ Quality & Safety. 29 (12): 1019–1032\. doi:10.1136/bmjqs-2019-010581. PMC 7785164. PMID 32532814.
68. ^ "Sharing electronic records with patients led to improved control of type two diabetes". NIHR Evidence (Plain English summary). 21 October 2020. doi:10.3310/alert_42103. S2CID 242149388.
69. ^ Jeong JW, Kim NH, In HP (July 2020). "Detecting usability problems in mobile applications on the basis of dissimilarity in user behavior". International Journal of Human-Computer Studies. 139: 102364. doi:10.1016/j.ijhcs.2019.10.001. S2CID 208105117.
70. ^ Hood M, Wilson R, Corsica J, et al. (December 2016). "What do we know about mobile applications for diabetes self-management? A review of reviews". Journal of Behavioral Medicine. 39 (6): 981–994\. doi:10.1007/s10865-016-9765-3. PMID 27412774. S2CID 29465893.
71. ^ "Diabetes eye exams: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 5 November 2024.
72. ^ Briscoe VJ, Davis SN (2006). "Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management". Clinical Diabetes. 24 (3): 115–21\. doi:10.2337/diaclin.24.3.115.
73. ^ Perlmuter LC, Flanagan BP, Shah PH, et al. (October 2008). "Glycemic control and hypoglycemia: is the loser the winner?". Diabetes Care. 31 (10): 2072–2076\. doi:10.2337/dc08-1441. PMC 2551657. PMID 18820231.
74. ^ Cox DJ, Gonder-Frederick L, Clarke W (February 1993). "Driving decrements in type I diabetes during moderate hypoglycemia". Diabetes. 42 (2): 239–243\. doi:10.2337/diabetes.42.2.239. PMID 8425660.
75. ^ Clarke WL, Cox DJ, Gonder-Frederick LA, et al. (August 1999). "Hypoglycemia and the decision to drive a motor vehicle by persons with diabetes". JAMA. 282 (8): 750–754\. doi:10.1001/jama.282.8.750. PMID 10463710.
76. ^ a b Cox DJ, Kovatchev BP, Anderson SM, et al. (November 2010). "Type 1 diabetic drivers with and without a history of recurrent hypoglycemia-related driving mishaps: physiological and performance differences during euglycemia and the induction of hypoglycemia". Diabetes Care. 33 (11): 2430–2435\. doi:10.2337/dc09-2130. PMC 2963507. PMID 20699432.
77. ^ Cox DJ, Gonder-Frederick LA, Kovatchev BP, et al. (2002). "The metabolic demands of driving for drivers with type 1 diabetes mellitus". Diabetes/Metabolism Research and Reviews. 18 (5): 381–385\. doi:10.1002/dmrr.306. PMID 12397580. S2CID 25094659.
78. ^ Chan M (2010). "Reducing cost-related medication nonadherence in patients with diabetes". Drug Benefit Trends. 22: 67–71\. Archived from the original on 4 March 2012. Retrieved 5 May 2010.
79. ^ Cui M, Wu X, Mao J, et al. (2016). "T2DM Self-Management via Smartphone Applications: A Systematic Review and Meta-Analysis". PLOS ONE. 11 (11): e0166718. Bibcode:2016PLoSO..1166718C. doi:10.1371/journal.pone.0166718. PMC 5115794. PMID 27861583.
80. ^ a b Safren SA, Gonzalez JS, Wexler DJ, et al. (2013). "A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes". Diabetes Care. 37 (3): 625–633\. doi:10.2337/dc13-0816. PMC 3931377. PMID 24170758.`{{cite journal}}`: CS1 maint: overridden setting (link)
81. ^ a b Gonzalez JS, Tanenbaum ML, Commissariat PV (October 2016). "Psychosocial factors in medication adherence and diabetes self-management: Implications for research and practice". The American Psychologist. 71 (7): 539–551\. doi:10.1037/a0040388. PMC 5792162. PMID 27690483.
82. ^ Chew BH, Vos RC, Metzendorf MI, et al. (September 2017). Chew BH (ed.). "Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews. 9 (9): CD011469. doi:10.1002/14651858.CD011469. PMC 6483710. PMID 28954185.
83. ^ Lustman PJ, Anderson RJ, Freedland KE, et al. (July 2000). "Depression and poor glycemic control: a meta-analytic review of the literature". Diabetes Care. 23 (7): 934–942\. doi:10.2337/diacare.23.7.934. PMID 10895843.
84. ^ Hussain S, Habib A, Singh A, et al. (December 2018). "Prevalence of depression among type 2 diabetes mellitus patients in India: A meta-analysis". Psychiatry Research. 270: 264–273\. doi:10.1016/j.psychres.2018.09.037. PMID 30273857. S2CID 52919905.
85. ^ Ali S, Stone MA, Peters JL, et al. (November 2006). "The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis". Diabetic Medicine. 23 (11): 1165–1173\. doi:10.1111/j.1464-5491.2006.01943.x. PMID 17054590. S2CID 25685073.
86. ^ Gonzalez JS, Peyrot M, McCarl LA, et al. (December 2008). "Depression and diabetes treatment nonadherence: a meta-analysis". Diabetes Care. 31 (12): 2398–2403\. doi:10.2337/dc08-1341. PMC 2584202. PMID 19033420.
87. ^ "Why don't children and young people engage with diabetes services?". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 15 March 2022. doi:10.3310/alert_49448. S2CID 247483863.
88. ^ Sharpe D, Rajabi M, Harden A, et al. (October 2021). "Supporting disengaged children and young people living with diabetes to self-care: a qualitative study in a socially disadvantaged and ethnically diverse urban area". BMJ Open. 11 (10): e046989. doi:10.1136/bmjopen-2020-046989. PMC 8515452. PMID 34645656.

## External links

[edit]

* American College of Physicians Diabetes Portal – Resources for patients and clinicians
* American Diabetes Association
* Prevent Diabetes Problems: Keep Your Diabetes Under Control Archived 2011-06-06 at the Wayback Machine – Self-care tips at the United States "National Diabetes Information Clearinghouse"

* v
* t
* e

Diabetes

Types|

* Type 1
* Type 2
* LADA
* Gestational diabetes
* Diabetes and pregnancy
* Prediabetes
* Impaired fasting glucose
* Impaired glucose tolerance
* Insulin resistance
* Ketosis-prone diabetes (KPD)
* MODY
* Type 1 2 3 4 5 6
* Neonatal
* Transient
* Permanent
* Type 3c (pancreatogenic)
* Type 3
* MIDD

Blood tests|

* Blood sugar level
* Biomarkers
* Glycated hemoglobin
* Glucose tolerance test
* Postprandial glucose test
* Fructosamine
* Glucose test
* C-peptide
* Noninvasive glucose monitor
* Insulin tolerance test

Management|

* Prevention
* Diet in diabetes
* Diabetes medication
* Insulin therapy
* intensive
* conventional
* pulsatile
* Diabetic shoes
* Cure
* Embryonic stem cells
* Artificial pancreas
* Other
* Gastric bypass surgery

Complications|

* Diabetic comas
* Hypoglycemia
* Ketoacidosis
* Hyperosmolar hyperglycemic state
* Diabetic foot
* ulcer
* Neuropathic arthropathy
* Organs in diabetes
* Blood vessels
* Muscle
* Kidney
* Nerves
* Retina
* Heart
* Diabetes-related skin disease
* Diabetic dermopathy
* Diabetic bulla
* Diabetic cheiroarthropathy
* Diabetic foot ulcer
* Hyperglycemia
* Hypoglycemia

Advocacy and
organizations|

* T1International
* Open Insulin Project
* Breakthrough T1D
* International Diabetes Federation
* World Diabetes Day
* Diabetes UK

Other|

* Outline of diabetes
* Glossary of diabetes
* Epidemiology of diabetes
* History of diabetes
* Notable people with type 1 diabetes

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template